Bioanalysis
Bioanalysis
Will Biosimilars Replace Biologics?
.custom-column-left-text {
float: left;
width: 50%;
padding-right: 10px;
}
.custom-column-right-text {
float: right;
width: 45%;
text-align:center;
}
@media only screen and (max-width: 600px) {
.custom-column-left-text,
.custom-column-right-text,
.custom-column-flc-ebook-text {
float:none;
width:80%;
margin:0 auto;
}
}
Biologic drugs came on the market with the production of
Development of an Affinity Capture - LC-MS/MS Assay for the Quantitation of Adalimumab in Human Plasma using BioBA Sample Preparation Kit
A Novel Strategy for the In-Process Stabilization of N-Oxide Metabolites in Hemolyzed Plasma Determined by LC-MS/MS
The Application of Research Grade MetabolitePilot™ Software for the Determination of Exenatide Catabolites Using HRAM With SWATH Acquisition
Stability Evaluation of Captopril in Human Blood by LC-MS/MS
Development of a Multi-Peptide Immunocapture – LC-MS/MS Assay for the Quantitation of a PEGylated Therapeutic in Rat and Dog Plasma
What Does it Take? | Biologic and Biosimilar Clinical Trials
.custom-column-left-text {
float: left;
width: 50%;
padding-right: 10px;
}
.custom-column-right-text {
float: right;
width: 45%;
text-align:center;
}
@media only screen and (max-width: 600px) {
.custom-column-left-text,
.custom-column-right-text,
.custom-column-flc-ebook-text {
float:none;
width:80%;
margin:0 auto;
}
}
It’s the much-anticipated Part II of our “What Does it Take” series (insert glorious trumpet announcement sound here).
Quantitation of Insulin Glargine and Major Metabolites in Human Plasma Using Hybrid LBA-LC/MS with Automated Magnetic Particle Processing
Impact of Plasma Hemolysis on the Recovery of Phenprocoumon in LC-MS/MS Chiral Assay
A Strategy for Maintaining Chromatographic Peak Shape Due to Incompatible Extract and Mobile Phase by LC-MS/MS